| abstract |
A therapeutic agent for hepatic diseases comprising a 1,3-dithiole-2-thione derivative is disclosed. The agent may be formed into tablets, granules, powders, capsules, suspensions, injections, and suppositories. Normal dose is from 0.1 to 100 mmg/kg/day for oral administration, and 0.02 to 20 mg/kg/day for injection or other forms of administration. The compounds decrease GOT and GPT values in serum dose dependently and are safer than Malotilate which is a known hepatic desease medicine. |